Inogen, Inc. (INGN)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: 20-day average dollar volume ~$1.43M is below the $5.0M liquidity floor, so no clean stop/limit fill exists for a $5.13 microcap. No pullback limit qualifies (countertrend — price below the SMA50 5.92 and below a declining SMA200 6.33 with MACD -0.21) and no breakout stop qualifies (no consolidation base above; strong downtrend at the 52-week low).
Company overview
Inogen, Inc. designs, manufactures, and sells oxygen concentrators for patients with chronic respiratory conditions. Its product lineup includes portable and stationary devices, such as the Inogen One and Inogen At Home, along with accessories. The company serves patients, healthcare providers, and insurers globally, and offers direct rental services.
Fundamental
fairInogen shows improving revenue trends and strong liquidity, but remains unprofitable with negative cash flow.
Inogen has strong liquidity (about $105.5M cash and short‑term investments as of 2026‑06‑30 and no traditional debt) and improving operating trends (FY2025 revenue $348.7M; Q2 2026 revenue $95.1M, +3% y/y; updated 2026 revenue guidance of $355–$361M). However, it remains unprofitable (TTM net margin ~-6.9% with negative ROIC) and still burns free cash flow (FCF yield ~-6%). Valuation is low on EV/Sales (~0.24), but the investment case hinges on converting the recent improvement into sustained positive EBITDA and cash flow amid reimbursement, competitive, and supply-chain pressures.
Sentiment
fairSentiment is divided, with positive EBITDA framing offset by concerns over revenue outlook and channel pressure.
The post-Q2 results/guidance update (announced) is the dominant near-term driver, with upbeat adjusted EBITDA framing and some post-earnings analyst positivity offset by revenue-outlook/channel-pressure headlines, leaving coverage split. Media sentiment cooled from a bullish May–July baseline (polarity_score ≈ +0.41) to roughly flat over the last ~14 days (polarity_score ≈ 0.00); moderate red-flag cap applied due to conflicting signals, while no regulator-confirmed investigation surfaced.
Technical
weakThe stock is in a strong downtrend, trading at 52-week lows, with oversold momentum indicating bounce risk only.
Chart quality is weak-bearish (bounce-only). INGN is in a strong downtrend (ADX14 45.5) that just printed a 52-week low at 5.06, trading below SMA20 5.37, SMA50 5.92, SMA200 6.33, EMA9 5.24 and EMA21 5.42. Momentum is deeply oversold — RSI14 31.0, Williams %R -87.6 — while MACD remains negative (-0.21) with only a marginal histogram tick to +0.01, so at best this is an oversold-bounce candidate, not a base or reversal. Score 2: mostly weak-bearish, bounce-only.
You’re looking at 2026-09-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.